logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Nature Reviews Clinical Oncology cover

Nature Reviews Clinical Oncology

IF82.2
Papers2355
Citations33364
Journal Papers 2397
Publication Date
delete
Optimizing the delivery of radiotherapy with artificial intelligence
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-24
delete0
PREAI
deleteEvangelia Katsoulakis; Issam El Naqa
deleteShare
deleteSave
Tambotatug pelitecan — a potential new second-line treatment option for SCLC
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-22
delete0
PREAI
deleteDavid Killock
deleteShare
deleteSave
Understanding and targeting the tumour matrisome
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-21
delete0
PREAI
deleteDharma Pally; Johanna I. Englund; Alexandra Naba
deleteShare
deleteSave
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-17
delete0
PREAI
deleteTim F. Greten; Mitchell Ho
deleteShare
deleteSave
Publisher Correction: Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-17
delete0
PREAI
deleteKathleen N. Moore; Oladapo O. Yeku; Brooke E. Howitt; Hagop Youssoufian; Joyce F. Liu
deleteShare
deleteSave
Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-16
delete0
PREAI
deleteDiana Romero
deleteShare
deleteSave
Publisher Correction: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-11
delete0
PREAI
deleteWilliam Jia; Ronghua Zhao; Howard L. Kaufman; Robert L. Martuza
deleteShare
deleteSave
Liver resection improves survival in patients with locally advanced HCC
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-07
delete0
PREAI
deletePeter Sidaway
deleteShare
deleteSave
Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-09-03
delete0
PREAI
deleteWilliam Jia; Ronghua Zhao; Howard L. Kaufman; Robert L. Martuza
deleteShare
deleteSave
Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-27
delete0
PREAI
deletePeter Sidaway
deleteShare
deleteSave
Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-26
delete0
PREAI
deleteMonireh Sadat Seyyedsalehi; Paolo Boffetta
deleteShare
deleteSave
Exploring the landscape of targetable alterations in patients with glioblastoma
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-19
delete0
PREAI
deleteElisa Aquilanti; Mehdi Touat; Pim French; Antonio Iavarone; David Capper; Marjolein Geurts; Rifaquat Rahman; Roel Verhaak; Matthias Preusser; Martin van den Bent; Patrick Y. Wen
deleteShare
deleteSave
Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-12
delete0
PREAI
deleteFen Saj; Lipika Goyal
deleteShare
deleteSave
How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-11
delete0
PREAI
deleteDaniel E. Spratt
deleteShare
deleteSave
The proteome comes of age, but precision oncology needs functional maps
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-10
delete0
PREAI
deleteEmanuel Petricoin; Thomas Conrads; Lance Liotta
deleteShare
deleteSave
AI-based augmentation of oncology clinical trials
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-07
delete0
PREAI
deleteAndrea Villa; Ashley L. Eadie; David Synnott; Rebecca Romanò; Max Piffoux; Evelyn Yi Ting Wong; Naomi Scheinerman; Daniel S. W. Tan; Filippo Guglielmo Maria de Braud; Miriam Koopman; Jarushka Naidoo; Madhusmita Behera; Selen Bozkurt; Susan Halabi; Rodrigo Dienstmann; Loic Verlingue; Arsela Prelaj; Ravi B. Parikh
deleteShare
deleteSave
HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-07
delete0
PREAI
deleteDavid Killock
deleteShare
deleteSave
Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-08-04
delete0
PREAI
deleteDiana Romero
deleteShare
deleteSave
More options, more questions in the management of early relapsed and/or refractory multiple myeloma
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-07-31
delete0
PREAI
deleteCarlyn Rose Tan; Sham Mailankody
deleteShare
deleteSave
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
deleteNature Reviews Clinical Oncology
IF82.2
delete2026-07-30
delete0
PREAI
deleteSolange Peters; Petros Grivas; Christophe Massard; Sara M. Tolaney; Michel Obeid
deleteShare
deleteSave